National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Can you apply?
This grant is for National Institutes of Health-supported investigator-initiated early phase clinical trials studying cancer treatment and diagnostic approaches. Eligible applicants typically include academic medical centers, research hospitals, cancer centers, and eligible 501(c)(3) research institutions that have NIH institutional support (Institutional Clinical and Translational Research Support). Applicants must be prepared to launch or expand human subjects clinical trials for cancer-related therapies or diagnostic innovations. The program supports projects with a strong preliminary research foundation and a clear pathway to clinical evaluation. Geographic scope is nationwide, and grants may support early-phase trials (Phase 1 and Phase 2) that test safety, feasibility, and preliminary efficacy of novel cancer interventions in human subjects.
This grant is for National Institutes of Health-supported investigator-initiated early phase clinical trials studying cancer treatment and diagnostic approaches. Eligible applicants typically include academic medical centers, research hospitals, cancer centers, and eligible 501(c)(3) research institutions that have NIH institutional support (Institutional Clinical and Translational Research Support). Applicants must be prepared to launch or expand human subjects clinical trials for cancer-related therapies or diagnostic innovations. The program supports projects with a strong preliminary research foundation and a clear pathway to clinical evaluation. Geographic scope is nationwide, and grants may support early-phase trials (Phase 1 and Phase 2) that test safety, feasibility, and preliminary efficacy of novel cancer interventions in human subjects.
Program description
Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Details
This grant is for National Institutes of Health-supported investigator-initiated early phase clinical trials studying cancer treatment and diagnostic approaches. Eligible applicants typically include academic medical centers, research hospitals, cancer centers, and eligible 501(c)(3) research institutions that have NIH institutional support (Institutional Clinical and Translational Research Support). Applicants must be prepared to launch or expand human subjects clinical trials for cancer-related therapies or diagnostic innovations. The program supports projects with a strong preliminary research foundation and a clear pathway to clinical evaluation. Geographic scope is nationwide, and grants may support early-phase trials (Phase 1 and Phase 2) that test safety, feasibility, and preliminary efficacy of novel cancer interventions in human subjects.
How to apply
Application links
Required documents
- NIH R01 application form (SF-424 R&R)
- Project Narrative (typically 15 pages for R01)
- Detailed Budget and Budget Narrative (for first 12-month budget period, then ongoing years)
- Biographical sketches (NIH format) for key personnel
- Research Plan including Specific Aims, Significance, Innovation, and Approach (with clinical trial methods)
- Data Safety Monitoring Plan and DSMB charter
- Evidence of IRB approval or pending IRB review
- Letters of institutional support and clinical department commitment
- Preliminary data/progress reports and published or submitted manuscripts
- Clinical trial design documentation (e.g., protocol outline, inclusion/exclusion criteria)
- Protection of Human Subjects documentation and informed consent form
- Resource Sharing Plans (e.g., data sharing, biospecimen sharing)
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.393 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$213,206,023
-
$56,551,552
-
$48,640,472
-
$47,009,863
-
$42,878,192
-
$37,448,862
-
$29,324,004
-
$26,395,336
-
$24,427,436
-
$23,149,727
Top States by Funding
- MA 10 awards $373.4M
- CA 10 awards $259.2M
- MN 4 awards $106.9M
- NY 7 awards $98.1M
- TN 7 awards $97.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.393). How funding has trended year over year.
| 2024 | $754,945,159 | |
| 2025 | $834,514,512 | |
| 2026 est. | $520,096,276 |
FAQ
What types of organizations can submit an R01 Clinical Trial Required application?
Academic medical centers, research-intensive hospitals, cancer centers, and 501(c)(3) research institutions eligible to receive NIH funding. Your institution must have NIH institutional support and clinical trial infrastructure in place.
What are the key differences between this grant and non-clinical R01s?
This mechanism specifically requires a clinical trial component as a mandatory element. Non-clinical R01s support basic or translational research only. This grant bridges laboratory findings to human subjects research, so clinical expertise and IRB approval are required.
What should my project narrative emphasize?
Emphasize the unmet clinical need, preliminary laboratory/preclinical data supporting the trial rationale, detailed study design, patient population definition, safety monitoring plans, and feasibility of patient recruitment. Strong preliminary findings and experienced clinical research team are essential.
How competitive are these applications typically?
R01 grants from NIH are highly competitive. Success rates for NCI clinical trial R01s typically range from 10-15%. Exceptional preliminary data, institutional support, and a credible clinical team substantially improve competitiveness.
What is the typical funding range?
NIH R01 grants typically support $250,000–$500,000 in annual direct costs, with project periods commonly extending 3–5 years. Exact budgets depend on trial complexity, patient numbers, and institutional costs.
💡 Tips for applicants
- Lead with strong preliminary data: Reviewers expect robust preclinical or early clinical evidence that justifies moving to human subjects. Use figures, tables, and published results to build credibility.
- Demonstrate clinical feasibility: Clearly establish patient accrual targets, recruitment timelines, and institutional patient populations. Include letters of support from clinical departments confirming access to patient populations and trial infrastructure.
- Detail safety monitoring: NIH reviewers scrutinize safety plans carefully for early-phase trials. Include Data Safety Monitoring Board composition, stopping rules, adverse event reporting procedures, and how you will protect human subjects.
- Budget strategically for trial costs: Clinical trials are expensive. Allocate realistic costs for patient visits, screening, biospecimen collection, outcome measurement, and regulatory compliance. Justify staffing for trial coordination and adverse event reporting.
- Align with NCI priorities: Review recent NCI funding announcements and strategic initiatives in your cancer type or therapeutic area. Frame your trial as addressing gaps in current treatment options or diagnostic approaches.
⚠️ Common mistakes
Applications often fail due to weak or insufficient preliminary data in humans, making reviewers skeptical about readiness for clinical trial launch. Another frequent issue is underestimating trial complexity—applicants may propose ambitious patient numbers or timelines that institutional infrastructure cannot support, or fail to demonstrate DSMB independence and rigorous safety monitoring protocols. Finally, many applications lack clear alignment with NCI strategic priorities or fail to convincingly articulate why the trial cannot be funded through traditional pharma partnerships.
Similar grants
- ROLLING Underground Storage Tank Cleanup Fund — State Water Resources Control Board (California)
- CLOSED Central Valley Tributaries — Department of Water Resources (California)
- CLOSED Multifamily Housing Program (MHP) — Department of Housing and Community Development (California)
- CLOSED Water Desalination Grant Program — Department of Water Resources (California)
- CLOSED 2021 Noxious Weed Grant Program — CA Department of Food and Agriculture (California)